MindBio Therapeutics Corp
CNSX:MBIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
MindBio Therapeutics Corp
CNSX:MBIO
|
CA |
MindBio Therapeutics Corp
Mindbio Therapeutics Corp. engages in developing psychedelic medicines to treat medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2023-05-05. The firm is focused on creating novel and emerging treatments for mental health conditions and is conducting lysergic acid diethylamide (LSD)-microdosing human clinical trials. The company has developed a multi-disciplinary platform for developing treatments and is involved in psychedelic medicine development. The company has completed Phase I clinical trials microdosing LSD in 80 patients, has a Phase II clinical trial in development microdosing LSD in patients with major depressive disorder, and has a Phase II clinical trial in development microdosing LSD in late-stage cancer patients experiencing existential distress. The firm invests in research that forms the basis for developing novel and clinically proven treatments, including digital technologies and interventions, to treat debilitating health conditions such as depression, anxiety, and other related mental health conditions.
Mindbio Therapeutics Corp. engages in developing psychedelic medicines to treat medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2023-05-05. The firm is focused on creating novel and emerging treatments for mental health conditions and is conducting lysergic acid diethylamide (LSD)-microdosing human clinical trials. The company has developed a multi-disciplinary platform for developing treatments and is involved in psychedelic medicine development. The company has completed Phase I clinical trials microdosing LSD in 80 patients, has a Phase II clinical trial in development microdosing LSD in patients with major depressive disorder, and has a Phase II clinical trial in development microdosing LSD in late-stage cancer patients experiencing existential distress. The firm invests in research that forms the basis for developing novel and clinically proven treatments, including digital technologies and interventions, to treat debilitating health conditions such as depression, anxiety, and other related mental health conditions.
